These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6935180)

  • 1. Basic requirements for long-term assays for carcinogenicity.
    Feron VJ; Grice HC; Griesemer R; Peto R; Agthe C; Althoff J; Arnold DL; Blumenthal H; Cabral JR; Della Porta G; Ito N; Kimmerle G; Kroes R; Mohr U; Napalkov NP; Odashima S; Page NP; Schramm T; Steinhoff D; Sugar J; Tomatis L; Uehleke H; Vouk V
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):21-83. PubMed ID: 6935180
    [No Abstract]   [Full Text] [Related]  

  • 2. Uncertainty estimates for low-dose-rate extrapolations of animal carcinogenicity data.
    Guess H; Crump K; Peto R
    Cancer Res; 1977 Oct; 37(10):3475-83. PubMed ID: 908002
    [No Abstract]   [Full Text] [Related]  

  • 3. False-positive and false-negative rates for carcinogenicity screens.
    Fears TR; Tarone RE; Chu KC
    Cancer Res; 1977 Jul; 37(7 Pt 1):1941-5. PubMed ID: 861930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to "use of Statistics when Examining Lifetime Studies in Rodents to Detect Carcinogenicity".
    Fears TR; Tarone RE
    J Toxicol Environ Health; 1977 Nov; 3(4):629-32. PubMed ID: 592430
    [No Abstract]   [Full Text] [Related]  

  • 5. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments.
    Peto R; Pike MC; Day NE; Gray RG; Lee PN; Parish S; Peto J; Richards S; Wahrendorf J
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):311-426. PubMed ID: 6935185
    [No Abstract]   [Full Text] [Related]  

  • 6. Statistical issues in interpretation of chronic bioassay tests for carcinogenicity.
    Gart JJ; Chu KC; Tarone RE
    J Natl Cancer Inst; 1979 Apr; 62(4):957-74. PubMed ID: 285297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for deployment of short-term assays for evidence of carcinogenicity.
    Drake JW; de Serres FJ; Darby WJ; Dunkel VC; Longfellow DG; Ott H; Purchase IF; Ramel C; Schlatter C; Smith EM
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):295-308. PubMed ID: 6935184
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 9. Design of cancer assays for pharmaceutical agents.
    Ciminera JL; Heyse JF; Mantel N; Pitot PC
    J Natl Cancer Inst; 1984 Jun; 72(6):1212. PubMed ID: 6587143
    [No Abstract]   [Full Text] [Related]  

  • 10. Cooperative programme on long-term assays for carcinogenicity in Japan.
    Odashima S
    IARC Sci Publ; 1980; (27):315-22. PubMed ID: 7439964
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of statistics when examining lifetime studies in rodents to detect carcinogenicity.
    Salsburg DS
    J Toxicol Environ Health; 1977 Nov; 3(4):611-28. PubMed ID: 592429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Carcinogenicity studies in experimental animals. I. Design and performance].
    Feron VJ; de Vrijer F; van der Heijden CA
    Ned Tijdschr Geneeskd; 1986 Jun; 130(23):1049-51. PubMed ID: 3724897
    [No Abstract]   [Full Text] [Related]  

  • 13. [Carcinogenicity studies in experimental animals. II. Interpretation of the results and significance for man].
    Feron VJ; de Vrijer F; van der Heijden CA
    Ned Tijdschr Geneeskd; 1986 Jun; 130(23):1051-4. PubMed ID: 3724898
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term and short-term screening assays for carcinogens: a critical appraisal.
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):1-426. PubMed ID: 6935176
    [No Abstract]   [Full Text] [Related]  

  • 15. Design of cancer assays for pharmaceutical agents: a reply.
    Boorman GA; Huff JE; Schwetz BA
    J Natl Cancer Inst; 1986 Aug; 77(2):589-90. PubMed ID: 3461218
    [No Abstract]   [Full Text] [Related]  

  • 16. Considerations in the interpretation of animal bioassays for chemical carcinogenicity.
    Griesemer RA
    Transplant Proc; 1984 Apr; 16(2):412-5. PubMed ID: 6372175
    [No Abstract]   [Full Text] [Related]  

  • 17. [Methodological approaches to the study of the carcinogenic properties of substances].
    Pylev LN; Vasil'eva LA; Pliss GB
    Vopr Onkol; 2000; 46(3):320-6. PubMed ID: 10976279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to "Use of Statistics when Examining Lifetime Studies in Rodents to Detect Carcinogenicity".
    Haseman JK
    J Toxicol Environ Health; 1977 Nov; 3(4):633-6. PubMed ID: 592431
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of carcinogenicity studies with aldrin and dieldrin.
    Ritper DL
    J Assoc Off Anal Chem; 1979 Jul; 62(4):900-3. PubMed ID: 500539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term assays to predict carcinogenicity. Statistical analysis of data from in-vitro assays of mutagenesis.
    Breslow N; Kaldor J
    IARC Sci Publ; 1986; (83):457-81. PubMed ID: 3305350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.